Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Total Current Assets : $34.00 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Freeline Therapeutics Holdings's total current assets for the quarter that ended in Sep. 2023 was $34.00 Mil.

Freeline Therapeutics Holdings Total Current Assets Historical Data

The historical data trend for Freeline Therapeutics Holdings's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Total Current Assets Chart

Freeline Therapeutics Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

26.09

89.05

258.18

128.29

67.63

Freeline Therapeutics Holdings Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Current Assets	Get a 7-Day Free Trial													74.10	67.63	63.87	45.81	34.00

Freeline Therapeutics Holdings Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Freeline Therapeutics Holdings's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	47.279	+	1.23	+	0	+	19.118
	=	67.63

Freeline Therapeutics Holdings's Total Current Assets for the quarter that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	29.452	+	2.823	+	0	+	1.721
	=	34.00

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Freeline Therapeutics Holdings (NAS:FRLN) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Freeline Therapeutics Holdings's Liquidation Value for the quarter that ended in Sep. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	29.452	-	19.179	+	0.75 * 0	+	0.5 * 0
=	10.27

Freeline Therapeutics Holdings Total Current Assets Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP

Website

https://www.freeline.life

Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.